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Rotavirus (RV) is the leading cause of severe gastroenteritis (GE) among infants and young children
worldwide, accounting for 453,000 deaths in children aged <5 years. In Latin America rotavirus causes
an estimated 15,000 deaths annually and accounts for 20–70% of acute gastroenteritis cases requiring
hospitalization. This results in an estimated annual cost of approximately US$86 million. The most com-
mon G type has been G1 (50%), followed by G4, G3 and G9, although regional and temporal variations
are signiﬁcant. There are currently two effective rotavirus vaccines: a single-strain, human attenuated-
based (RotarixTM, GlaxoSmithKline Biologicals), and a ﬁve-strain, bovine-human reassortant vaccine
(RotaTeqTM, Merck and Company). The pioneering strategy behind the development and licensure of
RotarixTM was part of a new paradigm for global vaccine research and development focusing on introduc-
tion ﬁrst in countries with greatest medical needs. Rotarix™ demonstrated high efﬁcacy and a good safety
proﬁle in Phase II and III clinical trials performed in Latin America. In the pivotal phase III study involving
11 Latin American countries a 2-year efﬁcacy of 81% (95% CI: 71–87) was achieved against severe rota-
virus acute gastroenteritis. A high protective efﬁcacy was observed against severe rotavirus gastroenter-
itis caused by G1 and non-G1 strains. RotarixTM proved to be safe regarding intussusception (IS) in a two-
dose vaccine schedule beginning at 6–12 weeks of age.
First registered in Mexico in July 2004, Rotarix™ gained World Health Organization (WHO) prequaliﬁ-
cation in February 2007 and has been introduced for routine use into the universal mass vaccination pro-
grams of Brazil, Panama, Mexico, Venezuela, Ecuador, Guatemala, Honduras, Colombia, Paraguay, Bolivia,
Peru, and El Salvador. The main factors inﬂuencing the decision-making process of introducing rotavirus
vaccines in Latin American countries included: (a) demonstration of good efﬁcacy/safety proﬁles; (b)
political decision to decrease mortality; (c) decision from ministries of health; (d) availability of data
on the disease burden; (e) cold chain available; and, importantly (f) the use of PAHO’s Revolving Fund
for the purchase of vaccines. Post-licensure studies have shown 76% (95% CI: 64–84%) effectiveness in
El Salvadoran children and 76% (95% CI: 58–86%) to 85% (95% CI: 53–94%) in Brazil. Observational studies
in Panama, Mexico, El Salvador and Brazil reported reduction in all-cause diarrhea-related hospitaliza-
tions at rates of 22–37%, 11–40%, 35–48%, and 17–48%, respectively. The decline in diarrhea-associated
deaths reached 35% (95% CI: 29–39%) in Mexico and ranged from 22% (95% CI: 6–45%) to 33% (95% CI:
15–52%) among Brazilian children. A low, increased risk of intussusception was detected among MexicanAVI, Global Alliance for Vaccines and Immunization; DALY, disability adjusted life-years; GDP, gross domestic product;
virus gastroenteritis; PATH, The Program for Appropriates Technologies in Health; CDC, US Centers for Disease Control
of the Bill and Melinda Gates Foundation; SVI, Sabin Vaccine Institute; NIH, National Institutes of Health; USIAD, US
, Instituto Evandro Chagas, Secretaria de Vigilância em Saúde, Ministério da Saúde, Avenida Almirante Barroso, 492,
07/2046; fax: +55 91 3214 2005.
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I. Perez Schael et al. / Trials in Vaccinology 1 (2012) 10–20 11infants within 7 days after ﬁrst vaccine dose [odds ratio, 5.8 (95% CI: 2.6–13)]. Continuous and expanding
post-licensure rotavirus surveillance studies are needed to better assess the effect of universal vaccina-
tion in Latin American countries and elsewhere.
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On a global scale rotavirus (RV) is the most important cause of
severe gastroenteritis (GE) among children, accounting for one-
third of all diarrheal hospitalizations and nearly half a million
deaths annually [1–3]. It is estimated that RV causes about
15,000 deaths, 75,000 hospitalizations, and 2 million outpatient
visits per year in Latin America and the Caribbean [4–5]. A great
diversity in serotype-composition over time of co-circulating RV
strains has been reported worldwide, with strains bearing G1-type
speciﬁcity being dominant in Latin America at the time pivotal
clinical trials with RV vaccines were performed [6,7].
Vaccination is considered the most effective public health strat-
egy to prevent RV disease and reduce the global burden of RVGE
[8]. The ﬁrst commercialized RV vaccine, RotaShield™, was licensed
in the United States in 1998 and recommended by the Advisory
Committee on Immunization Practices (ACIP) for routine immuni-
zation of infants. However, this vaccine was withdrawn from the
market before its ﬁrst year, based on evidence of an association
with intussusception (IS), an uncommon adverse event [9,10]. This
event resulted in several international initiatives designed to expe-
dite the development and introduction of new RV vaccines, partic-
ularly in those countries with greatest medical needs. Almost one
decade after the withdrawal of RotaShield™ two live-attenuated
oral rotavirus vaccines were licensed in 2006 and made available
commercially: a single-strain vaccine composed of an attenuated
human G1P[8] strain (RotarixTM; GlaxoSmithKline Biologicals)
and a ﬁve-strain human-bovine (G1, G2, G3, G4 and P[8] strains)
reassortant vaccine (RotaTeqTM; Merck and Company). RotaTeqTM
and RotarixTM were tested in more than 70,000 infants each before
licensure, proving to be safe and highly efﬁcacious (>85%) against
severe rotavirus gastroenteritis [11]. Results were made available
recently from phase III trials completed in Africa and Asia
[12–15], where an overall lower – though signiﬁcant – protective
efﬁcacy was achieved when compared to pivotal clinical studies
conducted in Latin America, Europe and the USA. In October
2009 the availability of these additional data from Africa and Asia
led WHO to recommend that rotavirus vaccines should be includedinto all countries’ Expanded Program of Immunization (EPI) world-
wide, especially in those with high diarrhea-associated mortality
[16].
Several recent, post-licensure studies have been conducted in
Latin American countries to assess vaccine effectiveness against se-
vere RVGE and the vaccine impact on childhood morbidity and
mortality [15,17–20]. Overall, vaccine effectiveness against hospi-
talization for severe RVGE surpassed 75%. In addition, a signiﬁcant
reduction was seen in hospitalizations for all-cause diarrhea
among children in Panama, Mexico and Brazil [15,17]. Recent
investigations in Mexico and Brazil have also demonstrated that
the vaccine has had a major impact on diarrhea-related deaths
[18–20]. Although the large phase III trial with RotarixTM in Latin
America convincingly demonstrated a lack of association between
the vaccine and intussusception at the level observed for Rota-
ShieldTM, post-licensure case-series and case-control studies in
Mexico and Brazil indicate a low increased risk of developing
intussusception (IS) in the 7-day window after vaccination [15].
A number of analyses on the economic impact of rotavirus vac-
cination in Latin American countries have shown a favorable cost-
effectiveness ratio with an important impact of vaccine cost in the
models [11]. The role of PAHO’s Revolving Fund, the GAVI Alliance
and vaccine manufacturers has been crucial in this context; and as
a consequence, there are currently 12 Latin American countries
that have introduced RotarixTM into their National Immunization
Programs [5]. Of these 10 use the revolving fund, two purchase
the vaccine through direct government-industry negotiation and
three receive GAVI support.
This paper reviews the novel pioneering strategy underlying the
development of the human RV vaccine Rotarix™ (GlaxoSmithKline
[GSK] Biologicals, Rixensart, Belgium), with particular focus on its
clinical development, licensure, introduction, and early post-licen-
sure impact in Latin America.
2. A new paradigm for vaccine development
In light of the urgent need to accelerate the development of new
RV vaccines, the World Health Organization (WHO) and Global
Table 1
Recommendations from the WHO-GAVI meeting in Geneva, February 2000.
1. The group strongly encouraged the rapid development of new RV vaccine
candidates. Trials of new RV vaccines must assess the potential risk of IS
with the use of the vaccine. Parallel testing of new RV vaccine candidates
in developed and developing countries was also recommended.
2. Further studies with RotaShield™ were considered ethical, given the
higher disease burden and potential higher beneﬁt/risk ratio in a
developing country. However, further testing must not occur without the
assurance that the vaccine will be available for general use should trial
results prove positive.
3. The need to conduct disease burden studies in selected developing
countries was emphasized.
4. The group also encouraged research activities on the pathogenesis and
epidemiology of IS and baseline incidence studies in countries interested
in testing new RV vaccines.
5. WHO to provide continuing support to the national regulatory authorities
of developing countries to reach international standards for vaccine
regulation.
6. Laboratory surveillance of RV strains should be continued.
Note: RV, rotavirus; IS, intussusceptions.
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ing in Geneva in February 2000 with the participation of interna-
tional agencies, ministries of health, scientists, and personnel
from the pharmaceutical industry. The aim was to develop strate-
gic recommendations to create appropriate conditions for the
prompt clinical development, licensure and introduction of new
RV vaccines into those countries with greatest medical need [21].
Surveillance of RV disease burden, strain distribution and back-
ground incidence of IS were considered essential to establish the
need for vaccination and risk-beneﬁt assessment (Table 1). Other
recommendations included parallel testing of candidate RV vac-
cines in developed and developing countries given the differences
in RV epidemiology between these settings, the development of
standard licensure requirements for national regulatory authori-
ties and the need for rigorous post-marketing surveillance for vac-
cine-related adverse events. This represented a new paradigm for
vaccine development and required a large-scale, coordinated col-
laborative research approach involving public and private health
institutions, international agencies and pharmaceutical companies
willing to conduct the necessary studies with associated costs and
risks.
Four RV vaccine candidates were available at the time of the
WHO-GAVI meeting: a human neonate G3P[6] candidate (Ruth
Bishop, Australia), a LLR lamb G10P[12] candidate (Lanzhou Insti-
tute of Biomedical Products, China), a ﬁve-strain human-bovine
(WC3) reassortant RV candidate (RotaTeq™; Merck Research Labo-
ratories, USA) and a single-strain human attenuated G1P[8] RV
candidate (Rotarix™, GSK). Both Merck and GSK accepted the chal-
lenge, but with different scientiﬁc and commercial approaches.
Based on clinical trial conduct, Merck focused its strategy predom-
inantly towards industrialized countries, such as the United States
and Europe, although vaccine safety was assessed in a number of
Latin American countries (Costa Rica, Guatemala, Jamaica and
Mexico, for a total of 5300 children) in one large Phase III study
[22]. GSK implemented a more diverse clinical development pro-
gram and proposed a strategy aiming to introduce a safe and efﬁ-
cacious RV vaccine ﬁrst to those countries with greatest disease
burden and medical need. Latin America was targeted based on
the good quality of previous research, including efﬁcacy of former
RV vaccines in this region and regional epidemiological data on the
burden of RV, coupled with the existence of the necessary infra-
structure to conduct clinical trials. The result was the construction
of one of the largest, multicenter, academic-industry research
teams—the Human Rotavirus Vaccine Study Group. Over a period
of 5 years, more than 10 Phase II and III clinical trials and healtheconomic studies were undertaken in 12 low- and middle-income
Latin American countries involving approximately 73,650 children.3. Burden of rotavirus disease
Studies of the burden of RV infection in Latin American children
date back to the late 1970s and early 1980s [23–31]. RV has long
been recognized to be a leading cause of acute childhood GE in
the region, accounting for 20–70% of GE cases depending on the
study endpoints (age group, diagnostic techniques used, outpatient
or inpatient setting). While diarrhea-associated deaths have fallen
signiﬁcantly in Latin America over the past 15 years due to im-
proved sanitation and appropriate use of oral rehydration [32],
studies within the ﬁrst 2000 decade conﬁrmed that RV infection
continued to impose a high burden of disease in this region [33–
37]. Cumulative estimates of RV-associated mortality risk in Latin
American children under 5 years were <1:1600 in Argentina and
Chile, 1:400–1:1800 in Colombia, Venezuela, Brazil and most of
Central America, and 1:100–1:400 in Peru, Bolivia and low-income
Central American countries [33–37]. Altogether these studies high-
lighted the rotavirus disease impact in the region and were of
importance at the time of decision-making process for vaccine
introduction in Latin American countries. Recent prospective stud-
ies suggest that RV causes 30–40% of diarrhea-associated emer-
gency room visits and 40–70% of hospitalizations among children
36 months or younger in Argentina, Chile and Venezuela [38]. Sim-
ilar hospitalization rates have been reported in Brazil (48%) and
Colombia (50%) [39,40]. In Chile and Venezuela, approximately
one in 70 children will be hospitalized and one in 20–30 will visit
the clinic for RV disease by the age of 5 years [41–43]. In Argentina,
one in six children born in 1995 visited a public hospital and one in
35 required hospitalization as a result of RV diarrhea before their
third year of life [34]. Similar hospitalization rates (one in 27) were
reported in another study in Cordoba, Argentina [44]. A multicen-
ter study conducted in 11 countries of this region by the Human
Rotavirus Vaccine Study Group before the initiation of the Phase
III clinical trial reported 49% rotavirus positivity among children
hospitalized with severe GE during the observation period, with al-
most all cases of severe RVGE occurring in children <24 months of
age [7]. In a recent meta-analysis including 11 observational stud-
ies of RV in Latin America and the Caribbean, the proportion of gas-
troenteritis cases due to RV was 24.3% and the incidence of RVGE
was 170 per 1000 children-years in the age group under 5 years
[45].4. Circulating rotavirus strains
Studies on RV serotype circulation in Latin America during the
last 20 years showed similar patterns to those observed in other
parts of the world [6,46]. In preparation for the large Phase III
safety and efﬁcacy trial of the human RV vaccine, a prospective,
hospital-based surveillance study was undertaken in 75 centers
in 11 Latin American countries [7]. At the time of this study, G1
was the most common strain overall (51%), followed by G4 and
G3, with G9 emerging as an important serotype in Brazil and Mex-
ico. Interestingly, very different serotype patterns were observed
between countries during the same season [7]. It has been sug-
gested that some strains, such as G9 serotype, may cause more se-
vere disease [47]; however, this has not been supported by other
studies [48]. As observed in other regions [6,48–52], the distribu-
tion of RV serotypes in Latin America ﬂuctuated over time with
particular serotypes temporarily predominating during given sea-
sons in individual countries, e.g. G4P[8] in 1998–2000 followed
by G9P[8] during 2002–2005 in Paraguay [53,54], G1P[8] in Colom-
bia, Uruguay, Brazil and Argentina [55–58], G9P[8] in Ecuador [59],
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[60,61], and G3P[8] in Mexico City during the late 1980s [48].
Uncommon RV serotypes infecting children in the region had
been occasionally reported. These included G types 12, 10, 8 and
5 and P types [1], [6] or [9], mostly as isolated cases
[6,46,58,60,62–64]. It was suggested that a mutated G4 strain
may have been responsible for a large outbreak of RVGE in Nicara-
gua in 2005 [65].
An extensive meta-analysis study of circulating serotypes be-
fore introduction of rotavirus in Latin America and the Caribbean
concluded that G1P[8], G2P[4] and G9P[8] were the most prevalent
P-G combinations, accounting for17.9%, 9.1% and 8.8% of isolates,
respectively [45].5. Intussusception in pre-licensure surveillance studies
In light of the experience with RotashieldTM, knowledge on IS
epidemiology and background incidence was considered critical
before mass vaccine use. Studies were then generated in an impor-
tant number of Latin American countries. IS incidence rates were
51 per 100,000 infant population in Chile [66], 30 per 100,000 in-
fant population in Panama [67] and 47 per 100,000 live births in
Venezuela [68]. A retrospective study conducted in Venezuela re-
ported an annual hospitalization rate for IS of 35 per 100,000 in in-
fants under 1 year [69]. Prior to the Phase III trial of the human RV
vaccine in Latin America, a large IS surveillance study was con-
ducted in 11 countries in the region [70]. The incidence of IS in in-
fants under 1 year was found to range from 3.8 per 100,000
population in Brazil to 105.3 per 100,000 population in Argentina,
with a mean incidence of 51 per 100,000. This wide range of inci-
dence rates seems to be in line with global observations that the
incidence of IS varies over time and between regions, even within
individual countries [71]. Demographic and clinical characteristics
of IS cases were as expected from previous studies. Most IS (89%)
occurred during the ﬁrst year of life, with peak incidence between
4 and 8 months of age and a predominance in boys of (male: fe-
male ratio, 1.3:1). Careful surveillance has not revealed any in-
creased risk of IS in large phase III studies of new vaccines to
date [22,72].6. Health economic studies of rotavirus burden
Extensive health economic evaluation was performed in the re-
gion during the period of decision making processes occurring
within the continent. Researchers from Latin American and Emory
University, supported by GSK, conducted studies to evaluate the
cost and health burden of RV disease and the cost-effectiveness va-
lue of RV vaccination compared to the existing situation in eight
countries from the region (Argentina, Brazil, Chile, Dominican
Republic, Honduras, Mexico, Panama and Venezuela) [73–79]. All
studies highlighted the signiﬁcant RV disease burden on Latin
American healthcare systems resulting in an average of 246 outpa-
tient visits, 24 hospitalizations and 0.6 deaths for every 1000 live
births during the ﬁrst 5 years of life and a total annual cost (med-
ical plus direct and indirect non-medical costs) of approximately
US$86 million. As might have been expected, health burden (mea-
sured in disability-adjusted life-years [DALYs]) was generally high-
est in lower-income countries and greatest cost burden (cost per
child) occurred in higher-income countries [76]. It was concluded
that a RV vaccination program in Latin America would reduce both
disease burden (deaths averted: 50–75%) and healthcare costs (51–
75%) [80]. According to the criterion established by the WHO [80],
RV vaccination was considered a very cost-effective health inter-
vention in six countries and cost-effective in all countries, even
in Honduras which had a very low income (gross domestic product[GDP] per capita: US$1001) [75]. Local cost-effectiveness results
were important for GAVI and other organizations in their role of
ﬁnancial assistance for universal use of RV vaccine in the poorest
countries. Of particular importance in this context was the PAHO’s
Revolving Fund for Vaccine Procurement which operates through a
system of bulk purchasing; since 2007 the Fund has secured the
supply of rotavirus vaccines, at affordable prices, for the national
immunization programs of countries in the Americas. Of note,
during the Sixth International Symposium on Rotavirus and
Rotavirus Vaccines, held in Mexico in July 2004, representatives
of the Ministries of Health of Latin America launched the
Mexico City Declaration to put forward a call to action that would
facilitate introduction of rotavirus vaccines in the Americas region
[81]. This would include a concerted effort including PAHO and
its Revolving Fund for Vaccine Procurement, the GAVI and vaccine
manufactures.7. Clinical studies of the human rotavirus vaccine
The vast rotavirus vaccine research experience in Latin America
dates back to the late nineties with the simian–human quadriva-
lent reassortant strain that resulted in the licensure of RotaShieldTM
in the United States of America (USA) in 1998 [82]. One of the piv-
otal trials was conducted in Venezuela with an efﬁcacy of 88% efﬁ-
cacy against severe rotavirus gastroenteritis during the ﬁrst year of
life. Unfortunately, however, the use of RotaShieldTM was short-
lived since it was withdrawn within 1 year of its introduction ow-
ing to an association with intussusception [9,10]. The conduct of
such early, large catchment vaccine trials in Latin America was
instrumental for the implementation of further strategies to evalu-
ate the new generation vaccines, mostly RotarixTM, albeit also with
RotaTeqTM. The decision of launching these new studies in Latin
America was taken mainly in light of a recommendation made dur-
ing a meeting in Geneva in 2000, organized by WHO and GAVI,
which denoted a new paradigm for vaccine development: trials
were to be conducted in parallel in industrialized and developing
countries [21].
A fundamental clinical study providing evidence for natural
protection, key for vaccine development, was performed in Mexico
[83]. This study demonstrated that in Mexican children two natu-
ral infections conferred 100% protection against a subsequent
symptomatic rotavirus infection and that repeated asymptomatic
infections were common. Protection against symptomatic rotavi-
rus infections became the main target and outcome variable for fu-
ture vaccine studies. The efﬁcacy and safety of the human RV
vaccine Rotarix™ was extensively evaluated in large randomized,
Phase II and III placebo-controlled trials involving more than
73,650 children in Latin America and Europe [84]. Results of a ran-
domized, double-blind, placebo-controlled Phase II study in three
Latin American countries (Brazil, Mexico and Venezuela) revealed
Rotarix™ to be safe, immunogenic and effective for the prevention
of severe GE in healthy infants [85]. Two oral doses of the vaccine
(104.7, 105.2 or 105.8 focus-forming units [ffu]) or placebo were
administered at 2 and 4 months of age concomitantly with other
routine infant immunizations (oral poliovirus vaccine given at least
14 days apart). A total of 2155 infants (1618 vaccines and 537 pla-
cebo recipients) were followed up to 1 year of age. Protective efﬁ-
cacy against severe and any RVGE from 15 days post-dose 2 was
higher in the 105.8 ffu group (86% and 70%, respectively) than in
the other two vaccine groups. The vaccine was found to be well tol-
erated, with rates of adverse events similar to placebo. A post hoc
analysis from this study to evaluate vaccine efﬁcacy (VE) in mild to
moderate malnourished children showed two doses of the human
RV vaccine to confer high protection against severe RVGE equally
to both malnourished and normal weight infants [86].
Table 2
Protective efﬁcacy of Rotarix™ in Latin American infants during the ﬁrst 2 years of life from 2 weeks post-dose 2 (mean duration of follow-up, 20 months) [87].
Type of GE Rotarix™ (Na = 7205) Placebo (Na = 7081) Vaccine efﬁcacy
Nb %b nb %b %b 95% CIc
RVGE
Severe 32 0.4 161 2.3 80.5 71.3, 87.1
Hospitalization 22 0.3 127 1.8 83.0 73.1, 89.7
Severe RVGE according to typed
G1 wild-type 10 0.1 55 0.8 82.1 64.6, 91.9
Pooled non-G1 (G2, G3, G4, G9) 24 0.3 105 1.5 77.5 64.7, 86.2
GE due to any cause
Severe 342 4.7 551 7.8 39.0 30.1, 46.9
Hospitalization 265 3.7 429 6.1 39.3 29.1, 48.1
a Number of subjects included in each group.
b Number/percentage of subjects reporting at least one speciﬁed episode in each group.
c 95% conﬁdence interval.
d Subjects appear in more than one category if more than one G-type was identiﬁed in the stool sample.
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large-scale, randomized, double-blind, Phase III trial involving a to-
tal of 63,225 healthy infants from 11 Latin American countries and
Finland. Subjects received two oral doses of the vaccine
(n = 31,673) or placebo (n = 31,552) at approximately 2 and
4 months of age [72]. Severe GE episodes were identiﬁed by active
surveillance. VE was evaluated in a subgroup of 20,169 infants
(10,159 vaccines and 10,010 placebo recipients). Rotarix™ was
found to provide high protection against severe RVGE as well as
signiﬁcantly reducing the rate of severe GE from any cause, and
was not associated with an increased risk of IS. VE against severe
RVGE and RV-associated hospitalization during the ﬁrst year of life
was 85% (p < 0.001) and reached 100% against more severe RVGE.
Hospitalization for diarrhea of any cause was reduced by 42%
(95% CI: 29–53%; p < 0.001). During the 31 days after each dose,
six vaccine recipients and seven placebo recipients had deﬁnite
IS (difference in risk, 0.32 per 10,000 infants; 95% CI: 2.91–
2.18; p = 0.78).
A subset of 15,183 Latin American infants participating in this
trial (7669 vaccines and 7514 placebo recipients) were followed
for severe GE of any cause and safety from dose 1 up to 2 years
of age [87]. Efﬁcacy follow-up for GE episodes was undertaken
from 2 weeks post-dose 2 (2-years efﬁcacy follow-up period; mean
duration, 20 months). VE against severe RVGE was 80.5% (95% CI:
71.3–87.1) (Table 2). Signiﬁcant protection was demonstrated indi-
vidually for G1, G3, G4 and G9 types, as well as against pooled non-
G1 strains (G2, G3, G4 and G9), with a trend for protection against
G2P[4] strains. VE for hospitalization due to RVGE reached 83.0%
(73.1–89.7) and for GE due to any cause was 39.3% (29.1–48.1).
No cases of IS were reported during the second year of follow-up.
In a recent double-blind, placebo-controlled study conducted
across six Latin American countries, two doses of RotarixTM proved
to be highly efﬁcacious [82% (95% CI: 54–94%)] against severe
RVGE by 12 months of age, when co-administered with routine
EPI vaccines, including OPV [88].
Based on these ﬁndings, it was concluded that two oral doses of
human RV vaccine are safe in Latin American infants and provide
sustained high protection against severe RVGE due to G1 and
non-G1 strains and related hospitalizations during the ﬁrst 2 years
of life, when the disease burden is the highest.8. Country-speciﬁc rotavirus vaccine introduction initiatives
One of the ﬁrst recommendations from WHO was that RV vac-
cination should be included into the National Immunisation Pro-
grams of regions where vaccine efﬁcacy data have suggested asigniﬁcant public health impact and where appropriate infrastruc-
ture and ﬁnancing mechanisms are available [82]. Subsequently,
when the efﬁcacy of rotavirus vaccines became evident in Asian
and African countries, WHO recommended that all infants world-
wide should be vaccinated against rotavirus, particularly in those
regions where mortality rates in children <5 years of age are
P10% [89]. This recommendation was regarded as crucial in the
acceleration towards achievement of the fourth Millennium Devel-
opment Goal 4 of a two-thirds reduction in the mortality rate
among children aged <5 years. Rotarix™ is currently licensed for
vaccination of infants in 123 countries in the Americas, Europe,
Australia, Africa and Asia, of which 27 have incorporated the vac-
cine into their national or regional immunization programs. As of
September 2011, 12 Latin American countries have introduced
Rotarix™ into their national expanded program on immunization
(EPI), including: Brazil (in 2006), Ecuador (2007), El Salvador
(2006), Mexico (2007), Panama (2006), Peru (2009), Colombia
(2009), Guatemala (2009), Honduras (2009), Bolivia (2008), Para-
guay (2010), and Venezuela (2006) (Fig. 1, Table 3). Just following
completion of large phase III trials conducted in Latin America,
Rotarix™ was ﬁrst licensed in Mexico during July 2004, where
the creation of a Special Vaccine Expert Committee led to mass
introduction of the vaccine in two steps: initial implementation
in only 14 of the 32 states (those with the highest rates of diarrhea
deaths), followed by nationwide use starting in March 2007. The
fact that Latin American countries were the ﬁrst in the developing
world to introduce rotavirus vaccination into their national immu-
nization programs provided these countries with several lessons
that have covered technical, operational, ﬁnancial and political is-
sues [4,5]. The human RV vaccine was only, after polio, the second
oral vaccine introduced into the universal mass vaccination pro-
grams of the region, requiring several programmatic adjustments,
including the implementation of surveillance programs for vaccine
safety, rotavirus strains circulation and impact evaluation. This has
served as a model for several countries worldwide which have re-
cently introduced universal rotavirus vaccination or are in the pro-
cess of adopting rotavirus vaccines in their national immunization
programs. Following the GAVI Alliance’s inclusion of RV vaccines to
the list of interventions available for eligible countries in Latin
America and its utilization by PAHO’s Revolving Fund, broader
implementation of RV vaccination in the region took place [90].
Of the 12 Latin American countries that have adopted universal
mass vaccination with RotarixTM in their public sector, 10 are cur-
rently utilizing the PAHO’s Revolving Fund in the process of pur-
chasing the vaccine at the lowest price in the market. It should
be pointed out in this context that GAVI approval of applications
from Bolivia, Guyana (RotaTeqTM in use) and Honduras, led to
Fig. 1. Latin American countries that have incorporated Rotarix™ into their expanded program on immunization (September 2011) (dates of introduction and birth cohorts).
⁄More recent data available from health authorities from each country and Pan American Health Organization. ⁄⁄Support provided by GAVI.
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2008 [90]. Early after starting the implementation of rotavirus vac-
cines into the national immunization programs, it was estimated
that about 77% of the 2007 birth cohort in Latin America was eligi-
ble to receive RotarixTM free of costs, for a total of more than 18
million doses administered.
Brazil is also one of the few countries in Latin America that
developed the capacity to produce the human RV vaccine. In this
regard, an agreement was signed in January 2008 between GSK
and the Brazilian Ministry of Health, aiming at full local manufac-
ture of the vaccine at Fundação Oswaldo Cruz, Rio de Janeiro, with-
in 4–5 years. The development of a full manufacturing capacity is
currently in a relatively advanced stage [Akira Homma, personal
communication].
9. Post-licensure studies with RotarixTM
The need for conducting vaccine-effectiveness evaluations un-
der ‘‘real conditions’’ gained high priority with the progressive
introduction of RotarixTM into the national immunization programs
of several countries across Latin America [91]. To date three case-
control studies to assess vaccine effectiveness have been per-
formed in Latin America: one in El Salvador (a lower-middle in-
come country, according to the World Bank), and two in Brazil(an upper-middle income country) (Table 3) [15,92–94]. In El Sal-
vador two doses of RotarixTM were highly effective [76% (95% CI:
64–84%)] against hospitalizations for rotavirus gastroenteritis, as
compared to the healthy controls [92]. In Recife, North-eastern
Brazil, vaccine effectiveness rates were both of 77% using RV neg-
ative controls (95% CI: 42–91%) and children with ARI [93]. In a
large case-control study conducted in Belém, Northern Brazil, vac-
cine effectiveness rates were as high as 78% (95% CI: 58–86%) using
neighborhood [94]. In a recent case-control study to assess vaccine
ﬁeld effectiveness in Mexico, RotarixTM was shown to provide 94%
(95% CI: 16–100%)] against hospitalization caused the unusual,
fully heterotypic G9P[4] RV strain [95].
To date, population-based time-trends of all-cause/RV gastro-
enteritis burden reductions after implementation of RotarixTM were
assessed in Panama, Mexico, El Salvador and Brazil (Table 3)
[18,96–99]. There were four studies conducted in upper middle in-
come countries (Panama, Mexico and Brazil) that reported a 17–
40% reduction in all-cause gastroenteritis hospitalizations in chil-
dren aged <5 years [18,96–99]. In El Salvador (a lower middle in-
come country), reduction rates of 69–81% were reported in
hospitalizations for RVGE [98]. Results from an active surveillance
in one sentinel hospital in São Paulo, Brazil, have also demon-
strated a 42% decline in hospitalizations for RV-related GE from
2004 to 2008 [100].
Table 3
Rotarix™ introduction into the expanded program on immunization in Latin America, vaccine effectiveness and impact on morbidity and mortality.
Country, income levelc Date of
introduction
into the EPI
Decision-making process used
by EPIa/MoHb
GAVI countries and PAHO
collaboration
Vaccine
coverage
in 2010
Vaccine effectiveness in case-
control studiesd (95% CI) d
Health impact of vaccination
Outpatient visits
and/or hospitalizations
for AGE
Mortality for AGE
Bolivia, Lower middle October 2008 –e Purchase through the use of PAHO’s
Revolving Fund and support by GAVI
76% – – –
Brazil, Upper middle March 2006⁄ Decision from MoH
Availability of epidemiological
data
Cold chain availableLarge G9
outbreak
Purchase of vaccines made directly
from the MoH at reduced prices
(U$7–8 per dose)
83% 85% (53–94%) using RV-negative
GE as controls[93]76% (56–86%)
using neighborhood controls
[94]
48% reduction in
children <1 year of
age [99]
17% reduction in
children <5 years of
age [18]
42% reduction in
rotavirus AGE in
children <5 years of
age [100]
39% and 33% reduction
rates in infants and
<5 years children,
respectively [19]
22% reduction in children
<5 years [18]
Colombia, Upper middle February 2009 – Purchase through the use of PAHO’s
Revolving Fund
74% – – –
Ecuador, Lower middle October 2007 Based on demonstration of
good efﬁcacy/safety proﬁles
WHO pre-qualiﬁcation PAHO
funding available
Purchase of vaccines through the use
of PAHO’s Revolving Fund
97% – – –
El Salvador, Lower middle October 2006 Signiﬁcant RV disease burden
High mortality rate associated
with rotavirus
First vaccine doses purchased directly
by MoH and thereafter through the
use of PAHO’s Revolving Funds
92% 76% (58%–86%) using
neighborhood controls [92]
35%–81% reduction
in children <5 years
[98]
–
Guatemala, Lower middle May 2009 – Purchase through the use of PAHO’s
Revolving Fund
38% – – –
Honduras, Lower middle January 2009 – Purchase through the use of PAHO’s
Revolving Fund and support by GAVI
– – – –
Mexico, Upper middle March 2007⁄⁄ High incidence of diarrhea
deaths in 14 states
Demonstration of good
efﬁcacy/safety proﬁlesCost-
effectiveness analysis
Purchase of vaccines based on local
decision, made directly by the MoH at
reduced prices (US$15 per course-2
doses)
90% – 11–40% reduction in
children <5 years
[97]
35% reduction in infants
[20]
Panama, Upper middle March 2006⁄⁄⁄ Decision from MoH within
program to improve health in
the country
First vaccine doses purchased directly by
MoH and,as from 2008, through the use
of PAHO’s Revolving Fund
89% – – –
Paraguay, Lower middle January 2010 – Purchase through the use of PAHO’s
Revolving Fund
56% – – –
Peru, Upper middle January 2009 – Purchase through the use of PAHO’s
Revolving Fund
75% – – –
Venezuela, Upper middle April 2006⁄⁄⁄⁄ Political decision to decrease
mortality
Availability of funds
Local data such as cost-
effectiveness analysisStrong
recommendation from vaccine
investigators
First vaccine doses purchased directly
by MoH and thereafter through the
use of PAHO’s Revolving Funds
49% – – –
AGE, Acute gastroenteritis; A, available.
[], Corresponding reference number.
Other issues related to vaccine introduction in some countries, as follows: ⁄Tech transfer agreement between Fiocruz/MoH and GSK, manufacturing in 4–5 years; ⁄⁄Creation of a Special Vaccine Expert Committee for decision;
⁄⁄⁄Medical community ‘‘positive-pressure’’ was critical, as a result of participation in phase III trial; ⁄⁄⁄⁄Weakness due to concomitant measles outbreak, promotion and training needs and acceptability issues in some states.
a Expanded Program on Immunization.
b Ministries of Health.
c According to the World Bank.
d For information on the pre-licensure multicenter efﬁcacy information, see topic clinical studies of the human rotavirus vaccine.
e Information currently not available.
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evaluated in three studies only conducted in Mexico and Brazil
[15,18–20]. Overall there was a decline in the range of 22–41% in
all-cause GE mortality among children aged <5 years in the post-
vaccination period [15,101].
Data are currently available from one study that evaluated con-
comitantly the potential risk of IS in Brazil and Mexico after rou-
tine use of RotarixTM [102]. A small, albeit signiﬁcant, increased
risk of IS was observed within 7 days following the ﬁrst vaccine
dose among Mexican infants [odds ratio, 5.8 (95% CI: 2.6–13.0)].
A lower risk of IS was identiﬁed in Brazil after the second dose
only, with an odds ratio of 1.9 (95% CI: 1.1–3.4). Data are also avail-
able from preliminary analyses of a post-marketing active surveil-
lance study for IS under way in 66 hospitals across Mexico,
covering a birth cohort of approximately 500,000 infants [103].
Taken the available data from Mexico and Brazil together, there
is a signal of a small, transient increased risk of intussusception
temporarily associated with administration of RotarixTM. Neverthe-
less, such a potential risk appears substantially lower than that
reported for the human-rhesus tetravalent reassortant vaccine
RotaShieldTM (Wyeth), suggesting that the substantive beneﬁts of
rotavirus vaccination far outweigh the risk of intussusception.10. Future challenges
The importance of post-marketing surveillance (PMS) following
the introduction of new RV vaccines has been well-recognized [82].
Latin American clinical researchers in association with GSK were
committed to evaluate Rotarix™ in PMS settings to further docu-
ment both the safety proﬁle of the vaccine and the overall public
health impact when administered under universal mass vaccina-
tion conditions. A large PMS safety study was to be conducted in
Mexico, speciﬁcally designed to evaluate the temporal association
between vaccine administration and deﬁnite IS, observed with the
RotaShieldTM vaccine. PMS case-control studies were also planned
to be conducted in El Salvador, Panama and Brazil to assess vaccine
effectiveness for the prevention of RVGE hospitalizations. Although
some of these studies have been extended to perform a long-term
monitoring of circulating RV strains in children hospitalized for
acute GE, a signiﬁcant amount of data are currently emerging on
the efﬁcacy of RotarixTM under ‘‘real conditions’’ in Latin America.
PMS studies are indeed essential to monitor RV strain circulation
following the introduction of RV vaccines into routine use, in an at-
tempt to assess whether or not there is any long-term interaction
between rotavirus vaccination and the strain ecology. Of note is the
recent apparent predominance of the G2P[4] serotype in North-
eastern Brazil [104,105]. Interpretation of these ﬁndings is limited
by the small sample sizes, short duration of surveillance and lack
of any comparison groups in these studies. However, it is notewor-
thy that G2P[4] RV strains have been previously documented to
display a cyclic pattern of occurrence in Brazil [106,107]. Further-
more, despite low vaccine coverage (50%) and 100% predomi-
nance of G2P[4] strains, Rotarix™ was found to provide high
protection against severe RVGE among vaccinated children [108].
Indeed, severe RVGE occurred in only 7% of vaccinated children
compared with 26% of non-vaccinated subjects (p < 0.05), with a
calculated odds ratio (OR) of 0.20 (95% CI: 0.029–1.24) [78]. RV
strain-speciﬁc surveillance conducted over several years will be
essential to fully elucidate this situation. The PMS case control
study in Brazil include an extended period of strain surveillance
of at least 3 years. Recent studies in Brazil, El Salvador, Mexico
and Panama have demonstrated a signiﬁcant decline in hospital-
izations for all-cause GE and GE-related deaths in children aged
<5 years after introduction of a rotavirus vaccine [19,20,96–99].
This suggests that continuous gathering of data on hospitalizationsfor GE and GE-related deaths in Latin America and elsewhere may
prove useful in assessing the effect of universal RV vaccination.
Although some preliminary data indicate a small, transient in-
crease of IS following the ﬁrst vaccine dose in Mexico, it is impor-
tant to maintain continued surveillance in several countries across
Latin America for episodes of IS and other serious adverse events
following the progressive introduction of RV vaccination in Latin
America. Of particular importance in the near future would be
studies addressing the possible impact on vaccine performance
of: (a) alternative schedules possibly including a neonatal vaccina-
tion; (b) altering breastfeeding practices; (c) introducing an inter-
val in relation to polio vaccination; (d) using zinc or probiotic
supplementation; and (e) the issue of apparent waning immunity
in the second year of life [3,15]. In addition to this, further studies
are needed to assess the impact of universal RV vaccination on key
epidemiological issues including herd protection and herd immu-
nity among unvaccinated infants, age distribution of rotavirus
cases, changing seasonality and duration of protection. Although
a progressive introduction of RV vaccination was seen in Latin
America and elsewhere during the past 5 years, concerted efforts
should be maintained and strengthened between PAHO, GAVI,
the manufacturers, other international partners and country
authorities in order to make vaccines available at the lowest prices
for those countries with the highest needs. In parallel with this
there is an urgent need for efforts to raise awareness of the scien-
tiﬁc evidence currently available which reasonably reassures the
safety, efﬁcacy, effectiveness and the substantial health impact of
rotavirus vaccines. It seems important to build a broad scientiﬁc-
based advocacy initiative for rotavirus vaccination, stressing the
current beneﬁts over risk of vaccination mainly to decision makers,
potential donors, scientiﬁc community, medical societies, opinion
leaders and ofﬁcial advisory bodies.11. Conclusions
The withdrawal of the ﬁrst licensed RV vaccine, RotaShield™,
yielded important lessons for the development of following gener-
ations of RV vaccines. The pioneering RV vaccine development
strategy undertaken by Latin American researchers and the manu-
facturer represented a new paradigm for global vaccine research
and development. This Human Rotavirus Vaccine Study Group
undertook a systematic development program including burden
of disease and IS baseline studies, Phase II and III trials to evaluate
the safety, immunogenicity and efﬁcacy of the human RV vaccine
(Rotarix™), health-economics assessments, and post-marketing
surveillance to assess vaccine effectiveness, safety and impact on
morbidity, mortality and RV strain circulation. This has resulted
in pioneering early vaccine introduction in a developing region of
the world, before introduction into western industrialized coun-
tries with a reasonably high, albeit improbable level of vaccine cov-
erage. By ﬁrst registering the vaccine in middle-income and
developing countries, it has been possible to accelerate vaccine
implementation into universal mass vaccination programs and
help to close the vaccine access gap between industrialized nations
and less developed societies. A number of pharmacoeconomic
analyses indicate that mass immunization with rotavirus vaccines
in Latin America is a cost-effective measure if vaccines can be pur-
chase at affordable prices. In the post-licensure period at least two
case-control, studies in Latin America have reassured the effective-
ness of RotarixTM under ‘‘real world conditions’’. Moreover, post-
licensure observational studies conducted in early introducer Latin
American countries revealed substantial nationwide reductions in
both gastroenteritis deaths and hospitalizations among infants
and young children. As to safety, although a small, transient clus-
tering of intussusception cases has been detected within 7 days
18 I. Perez Schael et al. / Trials in Vaccinology 1 (2012) 10–20after ﬁrst dose in Mexico and second dose in Brazil, the potential
risk appears to be sufﬁciently low in order not to outweigh the sig-
niﬁcant beneﬁts of rotavirus vaccination. Continuous surveillance
studies are needed to better assess the effect of rotavirus vaccines
on the burden of severe childhood gastroenteritis in Latin America,
as well as to further evaluate any potential risk of intussusception
following the progressive introduction of rotavirus vaccination.
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